First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study

Autor: Mayka Freire, Juan José Ríos-Blanco, A.J. Chamorro, X Pla, D Colunga, Xavier Pla-Salas, B Marí, María Victoria Egurbide-Arberas, Melany Pestaña-Fernández, F J García Hernández, A Soto, M Pestaña, Gerard Espinosa, Luis Trapiella-Martínez, Ana Belén Madroñero-Vuelta, Vicent Fonollosa-Pla, P Segovia, L Sáez Comet, A. Guillén del Castillo, Dolores Colunga-Argüelles, A B Madroñero, Alfredo Guillén-del Castillo, M Ruiz Muñoz, María Victoria Egurbide, G Verdejo, Jose Antonio Todolí-Parra, C. Tolosa, V. Fonollosa, Carles Tolosa-Vilella, J A Vargas Hitos, Mónica Rodríguez-Carballeira, Manuel Ruiz-Muñoz, R González León, M Pérez Conesa, M Rubio Rivas, E Tarí, R Lorenzo, E Calvo, Norberto Ortego-Centeno, José Antonio Vargas-Hitos, Carmen Pilar Simeón-Aznar, María Jesús Castillo-Palma, Luis Sáez-Comet, M Freire, C.P. Simeon, L. Trapiella, J J Ríos Blanco, M.J. Castillo, A Marín, J A Todolí, M Rodríguez Carballeira, Pablo Segovia-Alonso, N Ortego-Centeno, Xavier Corbella, C Carbonell, Nerea Iniesta-Arandia, N Iniesta, X Corbella, Adela Marín-Ballvé, E Callejas Moraga, Manuel Rubio-Rivas

Publikováno v: CLINICAL RHEUMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

The objective of the study is to determine the importance of the mode of onset as prognostic factor in systemic sclerosis (SSc). Data were collected from the Spanish Scleroderma Registry (RESCLE), a nationwide retrospective multicenter database creat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c0228badbb337641fe2f19a9ff96daa
https://doi.org/10.1007/s10067-017-3936-7

THU0256 CARDIAC INVOLVEMENT IN NEWLY DIAGNOSED SPANISH PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM THE RELES COHORT

Autor: F. Mitjavila Villero, E. Fonseca, G. Salvador Cervelló, Antoni Castro, Á. Robles Marhuenda, I. Perales Fraile, J. Álvarez Troncoso, A. Marín Ballvé, F. J. García Hernández, Guillermo Ruiz-Irastorza

Publikováno v: Annals of the Rheumatic Diseases. 79:355.1-355

Background:Cardiac involvement is one of the most important causes of disability and mortality in patients with systemic lupus erythematosus (SLE). Transthoracic echocardiography (TTE) is a sensitive and specific technique in detecting cardiac abnorm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e73df4412f97e6de9dbc12f9ac773ec5
https://doi.org/10.1136/annrheumdis-2020-eular.1633

No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis

Autor: M C, Cénit, C P, Simeón, V, Fonollosa, G, Espinosa, E, Beltrán, L, Sáez-Comet, E, Vicente-Rabaneda, F J, García-Hernández, L, Martínez-Estupiñán, M, Rodríguez-Carballeira, V, Hernández, P G, de la Peña, M, Fernández-Castro, F J, Narváez, A, Pros, M, Gallego, R, Ríos-Fernández, M T, Camps, A, Fernández-Nebro, M V, Egurbide, P, Carreira, M A, González-Gay, J, Martín, R G, Portales

Publikováno v: Tissue antigens. 80(3)

Systemic sclerosis (SSc) is a complex autoimmune disease which genetic component has not been yet completely understood. IL6 encodes a cytokine with a crucial role in the development of autoimmunity and fibrosis and its actions mainly are controlled

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ff9495f47d8f307feadc1e23beb7a925
https://pubmed.ncbi.nlm.nih.gov/22742541

Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

Autor: M, Ramos-Casals, F J, García-Hernández, E, de Ramón, J L, Callejas, A, Martínez-Berriotxoa, L, Pallarés, L, Caminal-Montero, A, Selva-O'Callaghan, J, Oristrell, C, Hidalgo, R, Pérez-Alvarez, M L, Micó, F, Medrano, R, Gómez de la Torre, C, Díaz-Lagares, M, Camps, N, Ortego, J, Sánchez-Román, C, Tolosa

Publikováno v: Clinical and experimental rheumatology. 28(4)

To analyse the safety and efficacy of the off-label use of rituximab in patients with severe, refractory systemic autoimmune diseases.In 2006, the Study Group on Autoimmune Diseases of the Spanish Society of Internal Medicine created the BIOGEAS proj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a44865041ff5d81354beddd101a06987
https://pubmed.ncbi.nlm.nih.gov/20525449

AB0698 MID-Term Effects of Rituximab in Connective Tissue Disorders Related Interstitial Lung Disease (ILD)

Autor: Vidya Limaye, Suzana Jordan, M. Matucci Cerinic, Valeria Riccieri, J.A. Gonzalez Nieto, F. Anguita Santos, Yannick Allanore, Jelena Blagojevic, Oliver Distler, S. Bellando Randone, F. J. García Hernández, A. Selva-O'Calaghan, Britta Maurer, Serena Guiducci, Paolo Airò, Jérôme Avouac, Gemma Lepri

Publikováno v: Annals of the Rheumatic Diseases. 74:1131.2-1131

Background The treatment of ILD remains a challenge for the rheumatologist. Recent studies suggested a potential short-term benefit of rituximab (RTX) on connective tissue diseases developing ILD. Objectives To compare RTX effects on ILD in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e211d9ca5d7a597b33c1398a4334972
https://doi.org/10.1136/annrheumdis-2015-eular.6310